<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00779285</url>
  </required_header>
  <id_info>
    <org_study_id>P04057</org_study_id>
    <secondary_id>EUDRACT NO. 2004-001177-25</secondary_id>
    <nct_id>NCT00779285</nct_id>
  </id_info>
  <brief_title>Safety Study of CAELYX in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines (Study P04057)(TERMINATED)</brief_title>
  <official_title>Cardiac Safety Profile of Caelyx Therapy in Anthracyclin Pretreated Metastatic Breast Cancer Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the cardiac safety of Caelyx in patients with
      metastatic breast cancer who have previously received chemotherapy with anthracyclines.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">August 2006</completion_date>
  <primary_completion_date type="Actual">August 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiac Events</measure>
    <time_frame>Every 4 weeks during 6 cycles.</time_frame>
    <description>A cardiac event was defined as a decrease in left ventricular ejection fraction (LVEF) of &gt;=20 points from baseline if the resting LVEF remained in the normal range, or a decrease of &gt;=10 points if the LVEF became abnormal (lower than the institutional lower limit of normal).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Breast Neoplasm</condition>
  <arm_group>
    <arm_group_label>Single-arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pegylated Lyposomal Doxorubicin (Caelyx) 50 mg/m2, given for 6 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated Liposomal Doxorubicin</intervention_name>
    <description>Pegylated Liposomal Doxorubicin (Caelyx) IV, 50 mg/m2 once every 4 weeks for 6 cycles or until disease progression, whichever is earlier. Patients still receiving clinical benefit after a total of 6 cycles of Caelyx, may continue therapy at the discretion of the investigator.</description>
    <arm_group_label>Single-arm</arm_group_label>
    <other_name>SCH 200746</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women with histologically or cytologically confirmed metastatic breast cancer (no
             prior chemotherapy for metastatic disease).

          -  Prior treatment with an anthracyclin-containing regimen in the adjuvant setting
             (cumulative dose &gt;240mg/m^2 and &lt;360mg/m^2 doxorubicin or &gt;430mg/m^2 and &lt;650mg/m^2
             epirubicin).

          -  Women &gt;18 years of age.

          -  Documented measurable and/or evaluable metastatic breast cancer by appropriate
             radiological imaging (computed tomography (CT) scan and/or magnetic resonance imaging
             (MRI)).

          -  Performance status of at least 60% (Karnofsky index) and a life expectancy of at least
             12 weeks.

          -  Left ventricular ejection fraction &gt;50%.

          -  Normal organ function, except if abnormal due to tumor involvement.

               -  Adequate bone marrow function as indicated:

                    -  Platelets &gt;100,000/mm^3

                    -  Hemoglobin &gt;9 g/dL

                    -  Neutrophils &gt;1,500/mm^3

               -  Adequate renal function as indicated by:

                    -  Serum Creatinine &lt;1.5 x the upper limit of normal

               -  Adequate liver function, as indicated by:

                    -  Bilirubin and aspartate aminotransferase (AST) or alanine aminotransferase
                       (ALT) &lt;2 times upper limit of normal (&lt;4 times upper limit of normal when
                       related to primary disease)

          -  Subjects must be capable to demonstrate their willingness to participate in the study
             and comply with its procedures by signing a written informed consent.

          -  Women of childbearing potential (includes women who are less than 1 year
             postmenopausal and women who become sexually active) must be using an acceptable
             method of birth control (e.g., hormonal contraceptive, medically prescribed
             intrauterine device (IUD), condom in combination with spermicide) or be surgically
             sterilized (e.g., hysterectomy or tubal ligation).

          -  Subjects must understand and be able to adhere to the dosing and visit schedules.

        Exclusion Criteria:

          -  Patient is pregnant or is breastfeeding.

          -  Patients with moderate or severe heart failure (New York Heart Association (NYHA)
             class III/IV).

          -  Hypersensitivity to anthracycline therapy or a history of severe hypersensitivity
             reactions to products containing CremophorÂ® EL (e.g., cyclosporin for injection
             concentrate and teniposide for injection concentrate).

          -  Prior chemotherapy for metastatic disease.

          -  Clinically significant hepatic disease (except liver metastases of primary disease).

          -  Uncontrolled bacterial, viral, or fungal infection.

          -  Radiotherapy in the last 4 weeks or prior radiation therapy to more than one-third of
             the hemopoietic sites.

          -  Any other currently known malignancy or pre-malignant lesions or any history of other
             malignancy within the past five years (except non-melanoma skin cancer and surgically
             cured cervical cancer).

          -  Symptomatic brain metastasis.

          -  Patients who are incapacitated, largely or wholly bedridden or confined to a
             wheelchair, and who have little or no ability for self-care.

          -  Current signs or symptoms of severe, progressive or uncontrolled renal, hepatic,
             hematologic, endocrine, pulmonary, cardiac, neurological or cerebral disease.

          -  Documented human immunodeficiency virus (HIV) infection.

          -  Any condition (medical, social, psychological) which would prevent adequate follow-up.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2008</study_first_submitted>
  <study_first_submitted_qc>October 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2008</study_first_posted>
  <results_first_submitted>February 11, 2010</results_first_submitted>
  <results_first_submitted_qc>February 11, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 10, 2010</results_first_posted>
  <last_update_submitted>June 18, 2015</last_update_submitted>
  <last_update_submitted_qc>June 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Caelyx</title>
          <description>Pegylated Lyposomal Doxorubicin (Caelyx) 50 mg/m2, given for 6 cycles</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Caelyx</title>
          <description>Pegylated Lyposomal Doxorubicin (Caelyx) 50 mg/m2, given for 6 cycles</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cardiac Events</title>
        <description>A cardiac event was defined as a decrease in left ventricular ejection fraction (LVEF) of &gt;=20 points from baseline if the resting LVEF remained in the normal range, or a decrease of &gt;=10 points if the LVEF became abnormal (lower than the institutional lower limit of normal).</description>
        <time_frame>Every 4 weeks during 6 cycles.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Caelyx</title>
            <description>Pegylated Lyposomal Doxorubicin (Caelyx) 50 mg/m2, given for 6 cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Events</title>
          <description>A cardiac event was defined as a decrease in left ventricular ejection fraction (LVEF) of &gt;=20 points from baseline if the resting LVEF remained in the normal range, or a decrease of &gt;=10 points if the LVEF became abnormal (lower than the institutional lower limit of normal).</description>
          <units>Cardiac Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Caelyx</title>
          <description>Pegylated Lyposomal Doxorubicin (Caelyx) 50 mg/m2, given for 6 cycles</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Maculopapulosus exanthema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Principal investigator agrees not to publish/publicly present any
interim results without prior Sponsor written consent and agrees to provide 30 days written notice prior to submission to permit review of abstracts/manuscripts which report any results. Sponsor has the right to review/comment/edit to ensure confidentiality, information accuracy, and that the presentation is fairly balanced. If the parties disagree, the investigator agrees to meet with Sponsor to discuss/resolve any disagreement.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

